In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.

BioPharmaceutical Deals ImmunoOncology

Philips Targets Bolt-On Deals That Meet Demand At The Point Of Care

Philips, a giant of the medical systems and software industry, maintains its strategic direction with organic and external growth. That was illustrated in one recent four-month period in which the group made seven acquisitions, adding to its non-invasive diagnostics portfolio Electrical Geodesics and bolstering its steps in therapeutic medical devices with the acquisition of Spectranetics. But whatever the target, the same ground rules apply.

Deals Medical Device Growth

Bristol/Medarex: A Transformational Acquisition Rooted In Collaboration

Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in immuno-oncology and by most accounts is the highlight of the pharma's "string of pearls" strategy.

Deals Business Strategies ImmunoOncology

In Vivo's Deals Of The Century: A Timeline

When it comes to deal-making, In Vivo's editors have always been quick to single out transactions that we feel will spark trends or otherwise have a major impact on the life sciences industry. Below, an expandable timeline of the deals we chose as bellwethers for pharma and medtech in each year of this still-young century and what we said about them at the time. (Free article.)

BioPharmaceutical Medical Device Deals
Advertisement

Human Capital
In The Life Sciences

Insights from In Vivo & EBD Academy's survey of senior executives


Recent Tweets from In Vivo


Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Amazon Versus Biotech: How The IPO Class Of '97 Worked Out

Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.

Financing Growth

How Cognitive Bias Undermines Value Creation In Life Sciences M&A

Life sciences mergers and acquisitions are typically based on perceived future value rather than objective financial parameters, but the cognitive biases inherent in subjective assessments can derail deals. Executives need to take emotion out of the equation and rely on relevant data to craft successful transactions.

Growth Deals

Time Is Money: Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?

Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.

Business Strategies Deals

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Ketamine May Shake Up The Treatment Of Major Depression

Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.

BioPharmaceutical Innovation

CRISPR/Cas9 Patent Battle: What's Happened, What's Next?

With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.

Regenerative Medicine Intellectual Property

Wright Place, Wright Time? Ortho Specialist's Focus Is Paying Off

In reinventing itself as a niche specialist in the orthopedic market, Wright Medical is putting efforts into maintaining leadership in the upper and lower extremities and building on its biologics strengths – a sales platform that was reinforced highly synergistically on the acquisition of Tornier. But for however long Wright Medical can remain independent, how does it balance value-based health care with strategic development plans?

Innovation Medical Device

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, September 2017

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Halozyme’s “Hat Collector” Approach To Human Capital: Virtue in Versatility

A Q&A on biopharma workforce recruitment, training and C-suite oversight with Halozyme's Ken Schultz, MD. A supplement to our feature on the In Vivo/EBD Academy survey, "Future-Proofing Human Capital in the Global Life Sciences: Does Biopharma Have the Right Stuff?

BioPharmaceutical Leadership

Inside Bayer Oncology: An Interview With Robert LaCaze

Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.

Business Strategies Deals

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

How To Make Your Drug Launch A Success

Recently launched drugs aren't meeting sales expectations and that's bad news for an industry whose revenues come from new products. Bain & Company surveyed senior launch executives to find the factors that lead to a successful launch.

BioPharmaceutical Commercial

Pivotal US Medtech Value Initiative Gaining Traction

As the US health care system shifts from a fee-for-service to a value-based approach, In Vivo asks Don May, EVP for Payment and Healthcare Delivery Policy at AdvaMed, about the association's renewed push behind the value frameworks and what he hopes the industry's drive to build on patient engagement, among other aims, will achieve.

Market Access Medical Device

Medtech Stakeholders Must Speak The Common Language Of Innovation And Reward Value

The current system of paying for medical technology includes perverse incentives, which means that the full benefits that innovation can deliver are not being accessed. So says AdvaMed chairman Nadim Yared, who believes the US association's new "value framework" is the way forward for medtech stakeholders. A key element is ensuring that all players speak a common language – one that also recognizes and promotes appropriate ways of paying for innovation.

Market Access Medical Device

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals In Depth: August 2017

Dermira aims to develop Roche's discontinued asthma antibody lebrikizumab in atopic dermatitis, in a deal worth $1.4 billion; Gilead entered CAR-T race with $11.9 billion buy of Kite Pharma. Biopharma funding was way up thanks to a $1.1 billion fundraise by Roivant Sciences.

Deals Market Intelligence

In Vivo's Deals Of The Month, September 2017

In Vivo's editors pick September's most significant deals, including lucrative partnerships for Halozyme and the pursuit of Dimension Therapeutics. (Free article.)

BioPharmaceutical Deals

CRISPR/Cas9 Patent Battle: What's Happened, What's Next?

With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.

Regenerative Medicine Intellectual Property
UsernamePublicRestriction

Register

Advertisement